FAQ

SU 11654

Known as: SU-11654, SU11654 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2013
01220022013

Related topics

Related topics

1 relation

Broader (1)

toceranib phosphate

Related mentions per year

Related mentions per year

2002-2018
20002005201020152020
SU 11654
toceranib phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.
Murine cancer models have been extremely useful for analyzing the biology of pathways involved in cancer initiation, promotion… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2010
2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… (More)
Is this relevant?
Review
2010
Review
2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or…
PURPOSE The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… (More)
Is this relevant?
Review
2009
Review
2009
Cancer Therapy: Clinical Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with…
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2008
2008
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
OBJECTIVE Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers. While Kit inhibitors have… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
OBJECTIVE To evaluate canine histiocytic sarcoma cell lines and tumor samples for dysregulation of the Kit/stem-cell factor (SCF… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
PURPOSE The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2003
2003
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
PURPOSE The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2002
2002
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?